Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Right Dose, Right Now randomized clinical trial
2017-002478-37Phase 4Active
- Sponsor
- VU University Medical Center
- Start
- Nov 2017
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vancomycin, ciprofloxacin, meropenem, ceftriaxone and cefotaxime in sepsis and Infection (2 arms), sponsored by VU University Medical Center. Primary endpoint: PK target attainment in the first 24 hours. Started Nov 2017; status: active.
02
Drugs
vancomycinciprofloxacinmeropenemceftriaxonecefotaxime
03
Conditions
sepsisInfection
Beyond the preview
Go deeper on 2017-002478-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002478-37.